An observational study in Adropin In Patients of OSA, sponsored by Aswan University. Not yet recruiting. Open to participants aged 20 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-21.
Sponsored by Aswan University · Observational
1. Objectives (Aim): To evaluate the role of serum adropin as a potential biomarker of endothelial dysfunction in OSA
1. Background and Rationale ( Introduction): Obstructive Sleep Apnea (OSA) is a common sleep-related breathing disorder characterized by recurrent episodes of partial or complete upper airway obstruction during sleep, resulting in intermittent hypoxia, sleep fragmentation, and increased sympathetic nervous system activity. These pathophysiological disturbances promote oxidative stress and systemic inflammation, which contribute to vascular injury and increase cardiovascular risk in patients with OSA (Li et al., 2020). Intermittent hypoxia has been shown to induce endothelial oxidative stress and inflammatory signaling in a dose-dependent manner, with greater severity of OSA being associated with more pronounced vascular dysfunction (Ryan et al., 2021).
Endothelial dysfunction is considered a key early mechanism linking OSA to cardiovascular disease. Intermittent hypoxia impairs endothelial homeostasis mainly through reduced nitric oxide (NO) bioavailability, increased endothelin-1 activity, and activation of pro-inflammatory pathways, leading to abnormal vascular tone and progression of atherosclerosis and hypertension (Javaheri and Barbe, 2020). Importantly, endothelial dysfunction may precede overt cardiovascular disease, highlighting its value as an early therapeutic target in OSA patients.
Identifying early biomarkers of endothelial dysfunction in OSA is therefore of major clinical importance for risk stratification and prevention of cardiovascular complications. Such biomarkers may also help in monitoring disease severity and evaluating response to therapeutic interventions, including continuous positive airway pressure therapy (Ryan et al., 2021).
Adropin is a peptide hormone encoded by the ENHO gene and is involved in energy homeostasis, lipid metabolism, and endothelial function. It enhances endothelial nitric oxide synthase activity and NO production, exerting protective effects on the vascular endothelium. Experimental and clinical studies have demonstrated that reduced circulating adropin levels are associated with endothelial dysfunction, insulin resistance, and increased cardiovascular risk (Altamimi et al., 2021).
Recent studies have demonstrated significantly lower serum adropin levels in patients with obstructive sleep apnea compared to healthy controls, with negative correlations between adropin levels and apnea-hypopnea index severity, as well as positive associations with endothelial function markers (Yosaee et al., 2020; Aşkın et al., 2022). Given the central role of endothelial dysfunction in OSA-related cardiovascular morbidity and the vasoprotective properties of adropin, evaluating serum adropin levels may represent a simple and reliable marker of endothelial dysfunction in patients with obstructive sleep apnea.
Aswan University is the lead sponsor of 47 studies on the registry; 21 are open to participants now.
Counted across the registry records on this site, refreshed daily.
The study will include adult obese participants who are referred to the Sleep Medicine/Chest outpatient clinic with suspected obstructive sleep apnea. Participants will undergo clinical assessment and overnight polysomnography (PSG) to confirm the diagnosis of OSA and determine its severity according to the apnea-hypopnea index (AHI).
Participants will be categorized into appropriate study groups according to the presence and severity of OSA. A suitable comparison group of obese participants without OSA may also be included, according to the study design.
The study population will include both males and females who meet the predefined inclusion criteria and provide informed consent to participate in the study
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
1- Adults aged 20-75 years. 2-obese Patients diagnosed with obstructive sleep apnea (OSA) confirmed by polysomnography.
3- Patients willing to provide written . 4- Patients not currently on medications affecting endothelial function (e.g., statins, ACE inhibitors) or able to temporarily withhold under medical supervision.
5- Ability to comply with study procedures and follow-up
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Fasting blood samples of Adropin were obtained by venipuncture in the morning following the sleep study.
Serum adropin levels (measured by ELISA)
* Serum adropin levels (measured by ELISA) * Association between serum adropin and endothelial function (Endothelin -1).
Time frame: 12 months
No study locations are listed for this record.
Plan to share: Undecided
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Aswan University